BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27175651)

  • 1. The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution.
    Kim ST; Ha SY; Lee J; Hong SN; Chang DK; Kim YH; Park YA; Huh JW; Cho YB; Yun SH; Lee WY; Kim HC; Park YS
    Medicine (Baltimore); 2016 May; 95(19):e3534. PubMed ID: 27175651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
    Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
    Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases.
    Patta A; Fakih M
    Anticancer Res; 2011 Mar; 31(3):975-8. PubMed ID: 21498724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computed Tomography and Magnetic Resonance Imaging in the Diagnosis of Primary Neuroendocrine Tumors of the Liver.
    Han Y; Li L; Sun H
    World Neurosurg; 2020 Jun; 138():723-731. PubMed ID: 32006738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
    Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
    Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
    Wu Z; Yu D; Zhao S; Gao P; Song Y; Sun Y; Chen X; Wang Z
    J Surg Res; 2018 May; 225():54-67. PubMed ID: 29605035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
    Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA
    Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
    Wolin EM
    Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma.
    Deutsch GB; Lee JH; Bilchik AJ
    J Am Coll Surg; 2015 Jul; 221(1):26-36. PubMed ID: 26027502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
    Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
    Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
    Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
    Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure.
    Okubo Y; Motohashi O; Nakayama N; Nishimura K; Kasajima R; Miyagi Y; Shiozawa M; Yoshioka E; Suzuki M; Washimi K; Kawachi K; Nito M; Kameda Y; Yokose T
    Diagn Pathol; 2016 Nov; 11(1):128. PubMed ID: 27821179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
    Ida H; Honma Y; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Kato K; Fukuda T; Boku N
    Invest New Drugs; 2019 Jun; 37(3):573-578. PubMed ID: 30267338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuroendocrine tumors: analysis of 252 cases].
    Chi YH; Jiang WC; Du F; Sun YK; Song Y; Yang L; Zhou AP; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):67-70. PubMed ID: 23648305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.